AC Camargo Hospital

Running trials

• Recruiting

  Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries

  NCT07539844· AbbVie· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America

  NCT07192991· Latin American Cooperative Oncology Group· Source

• Recruiting

  Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy

  NCT07285356· AC Camargo Cancer Center· Source

• Recruiting

  A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

  NCT06822543· Phase 2· Latin American Cooperative Oncology Group· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

• Recruiting

  Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery

  NCT07268846· AC Camargo Cancer Center· Source

• Recruiting

  Prophylactic Antibiotic Duration in Head and Neck Cancer Surgery (PROTECT-HN Trial)

  NCT07851857· Phase 3· AC Camargo Cancer Center· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Recruiting

  Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

  NCT07377747· Australia and New Zealand Sarcoma Association· Source

• Recruiting

  Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

  NCT06793137· Phase 2· AC Camargo Cancer Center· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

  NCT06356311· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil

  NCT06008353· AstraZeneca· Source

• Recruiting

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

  NCT05624554· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study of Novel Treatment Combinations in Patients With Lung Cancer

  NCT05633667· Phase 2· Gilead Sciences· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

  NCT05722015· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

  NCT05609968· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

• Recruiting

  A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

  NCT04831580· GOG Foundation· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

  NCT04974398· Phase 3· Akeso· Source

• Active, not recruiting

  A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

  NCT04662255· Phase 3· Loxo Oncology, Inc.· Source

• Recruiting

  Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach

  NCT04022109· University of Latvia· Source

• Active, not recruiting

  Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

  NCT03553836· Phase 3· Merck Sharp & Dohme LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Colorectal cancer3 recruiting
• Head and neck cancer2 recruiting
• Multiple myeloma2 recruiting
• Brain metastases1 recruiting
• Cervical cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Melanoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Phase 2· Incyte Corporation· Source

• Completed

  Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America

  NCT05924789· Latin American Cooperative Oncology Group· Source

• Completed

  A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

  NCT05328765· Latin American Cooperative Oncology Group· Source

• Completed

  Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers

  NCT04943445· Phase 2· Latin American Cooperative Oncology Group· Source

• Completed

  A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

  NCT04489888· Phase 4· Merck Sharp & Dohme LLC· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

  NCT04199104· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

  NCT04962919· Latin American Cooperative Oncology Group· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

  NCT03884101· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma

  NCT02166788· Phase 3· Melanoma and Skin Cancer Trials Limited· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Triple-negative breast cancer26 works · 1 trial
• Head and neck cancer19 works · 6 trials
• Endometrial cancer14 works · 2 trials